Utilization of Next Generation Multi-gene Panels Versus Single Gene Testing

      Introduction: In March of 2014, the Society of Gynecological Oncology released a Practice Statement highlighting the emerging use of cancer gene panels in the field of genetic testing. Subsequently, Myriad Genetics began offering a new multigene panel (myRisk), which analyzes twenty-five genes associated with hereditary cancer. Prior to the release of this statement, the majority of cancer genetic testing at our hospitals was performed for individual syndromes. Our objective was to determine the rates at which patients elect for BRCA1/2-only versus multigene panel testing after genetic counseling.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect